
<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Cystic Fibrosis Year in Review 2024</title>
    <script src="https://cdn.tailwindcss.com"></script>
    <script src="https://unpkg.com/feather-icons"></script>
    <link href="https://fonts.googleapis.com/css2?family=Poppins:wght@400;500;600;700&family=Inter:wght@300;400;500&display=swap" rel="stylesheet">
    <style>
        body {
            font-family: 'Inter', sans-serif;
        }
        h1, h2, h3, h4 {
            font-family: 'Poppins', sans-serif;
        }
        .bg-vertex-primary {
            background-color: #8A3083;
        }
        .bg-vertex-accent {
            background-color: #B52478;
        }
        .text-vertex-primary {
            color: #8A3083;
        }
        .text-vertex-accent {
            color: #B52478;
        }
        .border-vertex-primary {
            border-color: #8A3083;
        }
        .border-vertex-accent {
            border-color: #B52478;
        }
        .gradient-bg {
            background: linear-gradient(135deg, #8A3083 0%, #B52478 100%);
        }
        .stat-card {
            transition: transform 0.3s ease;
        }
        .stat-card:hover {
            transform: translateY(-5px);
        }
    </style>
</head>
<body class="bg-gray-50 text-gray-700">
    <!-- Header Section -->
    <header class="gradient-bg text-white py-8">
        <div class="container mx-auto px-4">
            <div class="flex flex-col md:flex-row justify-between items-center">
                <div class="mb-6 md:mb-0">
                    <h1 class="text-2xl md:text-3xl font-bold">Cystic Fibrosis Year in Review 2024</h1>
                    <p class="text-sm opacity-90">Journal of Cystic Fibrosis</p>
                </div>
                <div class="bg-white rounded-lg p-4 shadow-lg">
                    <div class="flex items-center">
                        <div class="mr-4">
                            <img src="https://ui-avatars.com/api/?name=Amel+Alameeri&background=8A3083&color=fff" alt="Author" class="w-12 h-12 rounded-full">
                        </div>
                        <div>
                            <h3 class="font-bold text-gray-800">Main Author</h3>
                            <p class="text-vertex-primary font-medium">Amel Alameeri</p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </header>

    <!-- Abstract Section -->
    <section class="py-8 bg-white shadow-sm">
        <div class="container mx-auto px-4">
            <div class="max-w-4xl mx-auto">
                <h2 class="text-xl font-bold mb-4 text-vertex-primary">ABSTRACT</h2>
                <div class="bg-gray-50 p-6 rounded-lg">
                    <p class="mb-4"><span class="font-semibold">Keywords:</span> Cystic fibrosis</p>
                    <p class="mb-4">The year 2024 marks a pivotal moment in the field of cystic fibrosis (CF) treatment, characterised by significant advancements in clinical care and an expanding body of literature on CF transmembrane conductance regulator (CFTR) modulators.</p>
                    <p class="mb-4">These CFTR therapies have transformed the landscape of CF management, offered systemic benefits, and established new guidelines for assessing clinical manifestations and therapies. Additionally, progress has been made in newborn screening (NBS), diagnosis, and understanding outcomes for individuals with CF-related metabolic syndrome or inconclusive diagnostic results.</p>
                    <p>However, amidst these clinical milestones, disparities in global access to CFTR modulators (CFTRm) persist, threatening to exacerbate existing inequities in CF care. This review provides a focused overview of the most impactful articles from 2024, highlighting both the clinical advancements and the pressing global accessibility challenges that define this transformative era in CF research and treatment.</p>
                </div>
            </div>
        </div>
    </section>

    <!-- Introduction Section -->
    <section class="py-12">
        <div class="container mx-auto px-4">
            <div class="text-center max-w-3xl mx-auto">
                <div class="inline-block px-4 py-2 bg-vertex-accent text-white rounded-full text-sm font-semibold mb-4">2024 Overview</div>
                <h2 class="text-3xl font-bold mb-6 text-gray-800">A Pivotal Year for Cystic Fibrosis Care</h2>
                <p class="text-lg text-gray-600 mb-8">2024 marked a transformative era in cystic fibrosis (CF) treatment, characterized by significant advancements in clinical care and an expanding body of literature on CF transmembrane conductance regulator (CFTR) modulators. CFTR therapies have profoundly changed CF management, offering systemic benefits and establishing new guidelines.</p>
                <div class="flex flex-wrap justify-center gap-4">
                    <div class="px-6 py-3 bg-white rounded-full shadow-md border border-gray-200 font-medium">Innovative Therapies</div>
                    <div class="px-6 py-3 bg-white rounded-full shadow-md border border-gray-200 font-medium">Global Challenges</div>
                    <div class="px-6 py-3 bg-white rounded-full shadow-md border border-gray-200 font-medium">Holistic Care</div>
                </div>
            </div>
        </div>
    </section>

    <!-- Global Standards & Inequities -->
    <section class="py-12 bg-gray-100">
        <div class="container mx-auto px-4">
            <div class="flex flex-col md:flex-row items-center mb-8">
                <div class="w-full md:w-1/2 mb-6 md:mb-0 md:pr-8">
                    <h2 class="text-2xl md:text-3xl font-bold mb-4 text-gray-800">Adapting Standards & Addressing Global Inequities</h2>
                    <p class="text-gray-600 mb-4">2024 saw significant updates in CF care standards while highlighting persistent global disparities in treatment access.</p>
                    <div class="flex items-center text-sm text-gray-500">
                        <i data-feather="alert-circle" class="mr-2"></i>
                        <span>Global inequities remain a critical challenge</span>
                    </div>
                </div>
                <div class="w-full md:w-1/2">
                    <div class="grid grid-cols-2 gap-4">
                        <div class="stat-card bg-white p-4 rounded-lg shadow-md">
                            <div class="text-vertex-primary text-3xl font-bold mb-2">4</div>
                            <div class="text-sm">Key Areas of Updated ECFS Standards</div>
                        </div>
                        <div class="stat-card bg-white p-4 rounded-lg shadow-md">
                            <div class="text-vertex-primary text-3xl font-bold mb-2">1.7x</div>
                            <div class="text-sm">More prevalent malnutrition in South Africa vs Canada</div>
                        </div>
                        <div class="stat-card bg-white p-4 rounded-lg shadow-md">
                            <div class="text-vertex-primary text-3xl font-bold mb-2">75k+</div>
                            <div class="text-sm">Undiagnosed individuals in 55 countries</div>
                        </div>
                        <div class="stat-card bg-white p-4 rounded-lg shadow-md">
                            <div class="text-vertex-primary text-3xl font-bold mb-2">82%</div>
                            <div class="text-sm">Of undiagnosed in low/middle-income countries</div>
                        </div>
                    </div>
                </div>
            </div>

            <div class="mt-8">
                <div class="grid md:grid-cols-2 gap-6">
                    <div class="bg-white p-6 rounded-lg shadow-sm hover:shadow-md transition-shadow">
                        <h3 class="font-bold text-lg mb-3 text-gray-800">Updated Standards of Care</h3>
                        <p class="mb-4">The European Cystic Fibrosis Society (ECFS) updated its "Standards of Care" guidelines across four key areas:</p>
                        <ul class="grid grid-cols-2 gap-2 mb-4">
                            <li class="flex items-center"><i data-feather="check" class="text-green-500 mr-2 w-4"></i> Diagnosis</li>
                            <li class="flex items-center"><i data-feather="check" class="text-green-500 mr-2 w-4"></i> Health maintenance</li>
                            <li class="flex items-center"><i data-feather="check" class="text-green-500 mr-2 w-4"></i> CF-specific issues</li>
                            <li class="flex items-center"><i data-feather="check" class="text-green-500 mr-2 w-4"></i> Planning for longevity</li>
                        </ul>
                        <p>These emphasize a <span class="font-semibold">multidisciplinary and holistic approach</span> to care.</p>
                    </div>
                    <div class="bg-white p-6 rounded-lg shadow-sm hover:shadow-md transition-shadow">
                        <h3 class="font-bold text-lg mb-3 text-gray-800">Global Disparities</h3>
                        <div class="space-y-4">
                            <div class="flex items-start">
                                <div class="bg-purple-100 rounded-full p-2 mr-3">
                                    <i data-feather="map" class="text-vertex-primary w-4"></i>
                                </div>
                                <div>
                                    <p><span class="font-semibold">South Africa:</span> Where newborn screening (NBS) and CFTRm are largely inaccessible, children with CF (cwCF) have <span class="font-semibold">significantly lower lung function</span> and <span class="font-semibold">1.7 times more prevalent malnutrition</span> compared to Canada.</p>
                                </div>
                            </div>
                            <div class="flex items-start">
                                <div class="bg-purple-100 rounded-full p-2 mr-3">
                                    <i data-feather="trending-up" class="text-vertex-primary w-4"></i>
                                </div>
                                <div>
                                    <p>While pwCF in Europe showed a <span class="font-semibold">gradual and consistent increase in lung functions</span> over 10 years, those in low-income countries did not.</p>
                                </div>
                            </div>
                            <div class="flex items-start">
                                <div class="bg-purple-100 rounded-full p-2 mr-3">
                                    <i data-feather="alert-triangle" class="text-vertex-primary w-4"></i>
                                </div>
                                <div>
                                    <p>The <span class="font-semibold">U.S. FDA extended ETI approval to 177 rare variants</span>, but this expansion has <span class="font-semibold">not been adopted by the European Medicines Agency</span>.</p>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

    <!-- CFTR Modulators Section -->
    <section class="py-12 bg-white">
        <div class="container mx-auto px-4">
            <div class="text-center max-w-3xl mx-auto mb-12">
                <h2 class="text-2xl md:text-3xl font-bold mb-4 text-gray-800">The Transformative Impact of CFTR Modulators (ETI)</h2>
                <p class="text-gray-600">CFTRm therapies, particularly elexacaftor-tezacaftor-ivacaftor (ETI), have demonstrated broad therapeutic potential across multiple aspects of CF health.</p>
            </div>

            <div class="grid md:grid-cols-3 gap-6 mb-8">
                <div class="stat-card bg-purple-50 p-6 rounded-lg border-l-4 border-vertex-primary">
                    <div class="flex items-center mb-3">
                        <div class="bg-vertex-primary text-white p-2 rounded-lg mr-4">
                            <i data-feather="user-check" class="w-5"></i>
                        </div>
                        <h3 class="font-bold text-gray-800">Expanding Eligibility</h3>
                    </div>
                    <ul class="space-y-3 text-sm">
                        <li class="flex">
                            <span class="font-bold text-gray-700 mr-2">•</span>
                            <span>ETI study with N1303K variant showed <span class="font-semibold">9 mmol/L reduction</span> in sweat chloride and <span class="font-semibold">17% ppFEV1 improvement</span></span>
                        </li>
                        <li class="flex">
                            <span class="font-bold text-gray-700 mr-2">•</span>
                            <span>French program found <span class="font-semibold">>50% of CF population</span> without F508del variants responded to ETI</span>
                        </li>
                        <li class="flex">
                            <span class="font-bold text-gray-700 mr-2">•</span>
                            <span><span class="font-semibold">152 unapproved CFTR variants</span> showed ≥10% of normal CFTR function with ETI</span>
                        </li>
                    </ul>
                </div>

                <div class="stat-card bg-purple-50 p-6 rounded-lg border-l-4 border-vertex-primary">
                    <div class="flex items-center mb-3">
                        <div class="bg-vertex-primary text-white p-2 rounded-lg mr-4">
                            <i data-feather="heart" class="w-5"></i>
                        </div>
                        <h3 class="font-bold text-gray-800">Gastrointestinal Health</h3>
                    </div>
                    <div class="text-sm">
                        <p>The 12-month RECOVER study showed <span class="font-semibold">significant improvements</span> in abdominal symptoms:</p>
                        <div class="mt-3 bg-white p-3 rounded-lg">
                            <p class="font-bold"><span class="text-vertex-primary text-lg">15.0</span> → <span class="text-vertex-primary text-lg">9.8</span> points</p>
                            <p class="text-xs">Total CF Abd-Scores decrease (p < 0.001)</p>
                        </div>
                    </div>
                </div>

                <div class="stat-card bg-purple-50 p-6 rounded-lg border-l-4 border-vertex-primary">
                    <div class="flex items-center mb-3">
                        <div class="bg-vertex-primary text-white p-2 rounded-lg mr-4">
                            <i data-feather="activity" class="w-5"></i>
                        </div>
                        <h3 class="font-bold text-gray-800">Liver Health</h3>
                    </div>
                    <ul class="space-y-3 text-sm">
                        <li class="flex">
                            <span class="font-bold text-gray-700 mr-2">•</span>
                            <span>Liver fibrosis markers remained stable</span>
                        </li>
                        <li class="flex">
                            <span class="font-bold text-gray-700 mr-2">•</span>
                            <span>Pediatric patients with advanced CFLD showed <span class="font-semibold">14.27% ppFEV1 improvement</span> (p = 0.007)</span>
                        </li>
                        <li class="flex">
                            <span class="font-bold text-gray-700 mr-2">•</span>
                            <span>ETI reduced inflammatory markers and faecal pathogens</span>
                        </li>
                    </ul>
                </div>
            </div>

            <div class="grid md:grid-cols-4 gap-4">
                <div class="stat-card bg-white p-4 rounded-lg shadow-md text-center">
                    <div class="text-vertex-primary text-2xl font-bold mb-1">46.21%</div>
                    <div class="text-xs">Increase in total adipose tissue ratio (p < 0.001)</div>
                </div>
                <div class="stat-card bg-white p-4 rounded-lg shadow-md text-center">
                    <div class="text-vertex-primary text-2xl font-bold mb-1">66%</div>
                    <div class="text-xs">Achieved negative Mycobacterium abscessus cultures</div>
                </div>
                <div class="stat-card bg-white p-4 rounded-lg shadow-md text-center">
                    <div class="text-vertex-primary text-2xl font-bold mb-1">14.8%→22.8%</div>
                    <div class="text-xs">Mucociliary clearance increase (p = 0.0002)</div>
                </div>
                <div class="stat-card bg-white p-4 rounded-lg shadow-md text-center">
                    <div class="text-vertex-primary text-2xl font-bold mb-1">2.12%</div>
                    <div class="text-xs">Risk reduction for sinus surgery (p < 0.0001)</div>
                </div>
            </div>

            <div class="grid md:grid-cols-2 gap-6 mt-8">
                <div class="bg-purple-50 p-6 rounded-lg">
                    <h3 class="font-bold text-lg mb-4 text-gray-800">Body Composition</h3>
                    <p>Automated CT-based analysis showed:</p>
                    <ul class="mt-3 space-y-2">
                        <li class="flex items-center">
                            <i data-feather="bar-chart" class="mr-2 text-vertex-primary w-4"></i>
                            <span><span class="font-semibold">46.21% increase</span> in total adipose tissue ratio (p < 0.001)</span>
                        </li>
                        <li class="flex items-center">
                            <i data-feather="bar-chart" class="mr-2 text-vertex-primary w-4"></i>
                            <span><span class="font-semibold">1.63% increase</span> in muscle ratio (p = 0.008) in adults after ETI therapy</span>
                        </li>
                    </ul>
                </div>
                <div class="bg-purple-50 p-6 rounded-lg">
                    <h3 class="font-bold text-lg mb-4 text-gray-800">Fertility & Pregnancy</h3>
                    <p>ETI has significantly improved fertility and pregnancy outcomes:</p>
                    <ul class="mt-3 space-y-2">
                        <li class="flex items-center">
                            <i data-feather="check" class="mr-2 text-green-500 w-4"></i>
                            <span>No foetal congenital anomalies reported</span>
                        </li>
                        <li class="flex items-center">
                            <i data-feather="alert-triangle" class="mr-2 text-yellow-500 w-4"></i>
                            <span>Intrauterine ETI exposure can <span class="font-semibold">lower immunoreactive trypsinogen levels</span>, potentially causing false-negative newborn screening results</span>
                        </li>
                    </ul>
                </div>
            </div>
        </div>
    </section>

    <!-- Treatment Burden Section -->
    <section class="py-12 bg-gray-100">
        <div class="container mx-auto px-4">
            <div class="text-center max-w-3xl mx-auto mb-12">
                <h2 class="text-2xl md:text-3xl font-bold mb-4 text-gray-800">Re-evaluating Treatment Burdens</h2>
                <p class="text-gray-600">The benefits of CFTRm have prompted discussions on reducing daily treatment burden, emphasizing a personalized approach.</p>
            </div>

            <div class="grid md:grid-cols-3 gap-6 mb-8">
                <div class="stat-card bg-white p-6 rounded-lg shadow-md">
                    <h3 class="font-bold text-lg mb-4 text-gray-800">SIMPLIFY-MCC Study</h3>
                    <ul class="space-y-3">
       
